Does NCT07223541 meet its primary endpoint at primary completion?

75% likely to miss · raimo

target LAG-3 · moa checkpoint-inhibition · failure mode target-redundant

1. premise investigator-led phase 2, n=72, oligo-metastatic ccRCC with SBRT; fianlimab (LAG-3) add-on on a cemiplimab (PD-1) backbone
2. premise LAG-3 efficacy in renal cell carcinoma is unproven — no positive phase 3 precedent in this substrate
3. inference a redundant second brake plus an underpowered superiority design (n=72) makes clearing a PFS superiority endpoint unlikely
4. prediction no PFS superiority over cemiplimab; primary endpoint not met